ASSOCIATION OF β-ADRENORECEPTION SYSTEM GENE POLYMORPHISMS AND NON-TOXIC GOITER IN PATIENTS WITH HEART FAILURE*
Predicting the course of heart failure (HF) is an urgent task of modern medical science. Given the increasing prevalence of the disease with age, it is necessary to take into account the presence of comorbid pathology. The aim of the research was to study the relationship between gene polymorphisms of the β-adrenoceptor system with non-toxic goiter (NTG) and the HF course. Materials and methods. The total of 285 patients with HF against the background of post-infarction cardiosclerosis were included into the study. Of these, 158 (55.42%) patients had a comorbidly unfavorable pathology - NTG. Genotyping of 4 polymorphisms (Gly389Arg of the β1-adrenoreceptor gene, Ser49Gly gene of the β1-adrenoceptor (β1-AP) gene, Gln27Glu of the β2-AP gene and Ser275 of the β3- G-protein subunit gene was performed usingpolymerase chain reaction (PCR). Genetic and epidemiological analysis was performed using the SNPStats software. The obtained results. The presence of the G-allele of the Ser49Gly polymorphism of the β1-AP gene is associated with an increase in the rate of NTG development (recessive heredity model, x2 = 3.719, p = 0.039). We found a tendency to the increase of NTG development rate (by 5.9%) in the presence of the allele C polymorphism of Ser275 gene GNβ3 (recessive model of heredity, x2 = 3,452, p = 0,068). The risk of "low triiodothyronine" syndrome development in patients with HF, running against the background of NTG increases in homozygotes (G / G) according to the polymorphism Ser49Gly (c, 145A> G) of the β1-AR gene (odds ratio (OR) = 9.19 (3.69-22.90), g = 0.044). In patients with HF, which runs against the background of NTG, with the presence of the G allele polymorphism Gln27Glu (c, 79C> G) of the β2-AP gene, the risk of reaching a combined endpoint within two years (OR = 3.05 (1.10-8.43) increases in a homozygous state and OR= 3.38 (1.47-7.82) in heterozygotes, at p = 0.008), the risk also increases with heterozygous (G / C) patients with the Gly389Arg (c, 1165G> C) polymorphism of the β1-AR gene in the presence of NTG (OR = 2.09 (1.00-4.37), p = 0.046). Conclusion. Congenital genetic differences in -adrenoceptor pathways may be associated with the development of non-toxic goiter and the long-term course of heart failure.
2. Bonnema SJ, Hegedus L A 30 year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Cur Op Endocr Metab Diab Obes. 2009; 16:379-384.
3. Brodde OE Beta(1) and beta(2) adrenoreceptor polymorphisms: Functional importance, impact on cardiovascu-lar diseases and drug responses. Phrmacol Ther. 2008; 117: 1-29.
4. Ponikowski P, Voors AA, Anker SD ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart. Fail. - 2016.
5. Pyvovar S, Rudyk I, Lozyk T Sindrom «nizkogo triyodtironina» i techeniye serdechnoy nedostatochnosti. Geor-gian Medical News. 2019; 4 (289): 79-85. [in Russian]
6. Pyvovar S, Rudyk I, Lozyk T Prohnozuvannya perebihu sertsevoyi nedostatnosti u khvorykh z netoksychnym zobom z urakhuvannyam funktsiyi shchytopodibnoyi zalozy. ScienceRise. Medical Science. 2019; 4.
7. Ma ST, Zhao W, Liu D Association between β1 adrenergic receptor gene Arg389Gly polymorphism and risk of heart failure: a meta-analysis. Genet Mol Res. 2015; 14: 5922-9.
8. Krohn KD, Führer Y, Bayer M Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter. Endocr Rev. June 2005; 26(4): 504-24.
9. Kim C, Reed L Thyroid Hormone and Adrenergic Signaling. Arq Bras Endocrinol Metab. 2004; 48(1): 171-175.
10. Sheppard R, Hsich E, Damp J. Investigators GNB3 C825T Polymorphism and Myocardial Recovery in Peripar-tum Cardiomyopathy Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study. Circ Heart Fail. 2016; 9: e002683
11. Rathz DA, Brown KM, Kramer LA Amino acid 49 polymor¬ phisms of the human beta1¬adrenergic receptor affect agonist¬pro¬ moted trafficking. J Cardiovasc Pharmacol. 2002; 39: 155-160.
12. Panebra A, Wang WC, Malone MM Common ADRB2 haplotypes derived from 26 polymorphic sites direct be-ta2-adrenergic receptor expression and regulation phenotypes. PLoS One. 2010; 29: e11819.
13. Covolo L, Gelatti U, Metra M Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J. 2004; 25: 1534–1541.
14. Levin M, Marullo S, Muntaner O The myocardium protective Gly49 variant of the beta1 adrenergic receptor ex-hibits of consti¬ tutive activity and increased desensitization and down regulation. J Biol Chemistry. 2002; 277: 30429-30435.
15. Pyvovar S, Rudyk I, Lozyk T Vzaémozyazok polimorfizmu heniv systemy β-adrenoretseptsiyi z syndromom «nyzkoho» tryyodtyroninu u khvorykh z sertsevoyu nedostatnistyu. Polski merkuriusz lekarski. 2019. 4
16. Wagoner L, Craft L, Zengel P Polymorphisms of the betal-adrenergic receptor predict exercise capacity in heart failure. Am Heart J. 2002; 144: 840-846.
This work is licensed under a Creative Commons Attribution 4.0 International License.